MA47206A - Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 - Google Patents

Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3

Info

Publication number
MA47206A
MA47206A MA047206A MA47206A MA47206A MA 47206 A MA47206 A MA 47206A MA 047206 A MA047206 A MA 047206A MA 47206 A MA47206 A MA 47206A MA 47206 A MA47206 A MA 47206A
Authority
MA
Morocco
Prior art keywords
tim
antibodies
cancer treatment
treatment methods
cancer
Prior art date
Application number
MA047206A
Other languages
English (en)
Inventor
Dmitri Bobilev
Andrew R Ferguson
Kristen Anne Mceachern
Jing Wang
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MA47206A publication Critical patent/MA47206A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA047206A 2017-01-09 2018-01-09 Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3 MA47206A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762444354P 2017-01-09 2017-01-09
US201762582272P 2017-11-06 2017-11-06

Publications (1)

Publication Number Publication Date
MA47206A true MA47206A (fr) 2019-11-13

Family

ID=61163782

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047206A MA47206A (fr) 2017-01-09 2018-01-09 Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3

Country Status (14)

Country Link
US (2) US11926665B2 (fr)
EP (1) EP3565594A1 (fr)
JP (2) JP7118073B2 (fr)
KR (1) KR102671283B1 (fr)
CN (1) CN110382000A (fr)
AU (1) AU2018205401A1 (fr)
BR (1) BR112019014169A2 (fr)
CA (1) CA3049536A1 (fr)
IL (1) IL267803A (fr)
MA (1) MA47206A (fr)
MX (1) MX2019008208A (fr)
SG (1) SG10201913083SA (fr)
TW (2) TWI793094B (fr)
WO (1) WO2018129553A1 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016150899A2 (fr) 2015-03-23 2016-09-29 Bayer Pharma Aktiengesellschaft Anticorps anti-ceacam6 et leurs utilisations
MA41867A (fr) * 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
AU2017343621B2 (en) 2016-10-11 2021-12-02 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
SG11201903867YA (en) * 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
US11155624B2 (en) * 2016-11-01 2021-10-26 Anaptysbio, Inc. Antibodies directed against programmed death-1 (PD-1)
CN110382000A (zh) 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
KR102606252B1 (ko) 2017-01-09 2023-11-23 테사로, 인코포레이티드 항-pd-1 항체로 암을 치료하는 방법
CN110913911A (zh) 2017-05-18 2020-03-24 特沙诺有限公司 用于治疗癌症的组合疗法
AU2018341479B2 (en) 2017-09-26 2022-02-17 Tesaro, Inc. Niraparib formulations
EP3697442A4 (fr) 2017-09-30 2021-07-07 Tesaro, Inc. Polythérapies pour le traitement du cancer
CA3076859A1 (fr) 2017-10-06 2019-04-11 Tesaro, Inc. Polyrherapies et leurs utilisations
KR20200109339A (ko) * 2018-01-16 2020-09-22 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체를 사용하여 암을 치료하는 방법
CN113330007A (zh) 2018-10-03 2021-08-31 特沙诺有限公司 尼拉帕利游离碱的晶体形式
WO2020072797A1 (fr) 2018-10-03 2020-04-09 Tesaro, Inc. Sels de niraparib
AU2019371457A1 (en) * 2018-11-01 2021-05-20 Merck Patent Gmbh Anti-TIM-3 antibodies
KR20210104704A (ko) 2018-12-19 2021-08-25 바이엘 악티엔게젤샤프트 항 ceacam6 및 tim3 항체의 제약 조합물
CN113614109A (zh) 2018-12-21 2021-11-05 Ose免疫疗法公司 双功能抗pd-1/il-7分子
KR20210102327A (ko) * 2019-01-11 2021-08-19 일라이 릴리 앤드 캄파니 암 치료를 위한 tim-3 항체 및 다른 체크포인트 억제제와의 조합
WO2020165374A1 (fr) 2019-02-14 2020-08-20 Ose Immunotherapeutics Molécule bifonctionnelle comprenant il-15ra
WO2021122866A1 (fr) 2019-12-17 2021-06-24 Ose Immunotherapeutics Molécules bifonctionnelles comprenant un variant de l'il-7
CA3171557A1 (fr) 2020-04-14 2021-10-21 Marc S. BALLAS Traitement combine pour le cancer impliquant des anticorps anti-icos et anti-pd1, impliquant eventuellement en outre des anticorps anti-tim3
CN115397861A (zh) 2020-04-14 2022-11-25 葛兰素史密斯克莱知识产权发展有限公司 用于癌症的组合治疗
WO2022006091A1 (fr) * 2020-06-29 2022-01-06 Anovent Pharmaceutical (U.S.), Llc Formulation biopharmaceutique d'anticorps monoclonaux thérapeutiques anti-pd-1, anti-pd-l1, et anti-vegfr et procédé de traitement de nsclc par inhalation
WO2022148781A1 (fr) 2021-01-05 2022-07-14 Institut Curie Association d'activateurs de mcoln et d'inhibiteurs de point de contrôle immunitaire
AU2022253351A1 (en) 2021-04-09 2023-10-12 Ose Immunotherapeutics New scaffold for bifunctional molecules with improved properties
WO2022214652A1 (fr) 2021-04-09 2022-10-13 Ose Immunotherapeutics Échafaudage pour molécules bifonctionnelles comprenant des domaines de liaison pd-1 ou cd28 et sirp
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
KR20240051162A (ko) 2021-09-02 2024-04-19 도이체스크레브스포르슝스젠트룸스티프퉁데스외펜트리헨레크츠 부작용이 감소된 항-cecam6 항체
WO2024003360A1 (fr) 2022-07-01 2024-01-04 Institut Curie Biomarqueurs et leurs utilisations pour le traitement du neuroblastome
WO2024028386A1 (fr) 2022-08-02 2024-02-08 Ose Immunotherapeutics Molécule multifonctionnelle dirigée contre cd28
WO2024200826A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipides ciblée au niveau de cellules immunitaires activées pour l'expression d'une molécule inhibitrice de cellules immunitaires et son utilisation
WO2024200823A1 (fr) 2023-03-30 2024-10-03 Ose Immunotherapeutics Nanoparticule à base de lipide ciblant des cellules immunitaires activées pour l'expression d'une molécule d'amélioration de cellule immunitaire et son utilisation

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4828981A (en) 1983-08-24 1989-05-09 Synbiotics Corporation Immunoassays for determining Dirofilaria immitis infection using antiidiotype monoclonal antibody reagents
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
EP0557459B1 (fr) 1990-11-13 1997-10-22 Immunex Corporation Genes de fusion selectionnables bifonctionnels
EP0804590A1 (fr) 1993-05-21 1997-11-05 Targeted Genetics Corporation Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
US5464758A (en) 1993-06-14 1995-11-07 Gossen; Manfred Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
US5814618A (en) 1993-06-14 1998-09-29 Basf Aktiengesellschaft Methods for regulating gene expression
US6843987B2 (en) 2000-02-02 2005-01-18 Schering Corporation Mammalian cytokines; receptors; related reagents and methods
FR2814642B1 (fr) 2000-10-03 2005-07-01 Ass Pour Le Dev De La Rech En Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
US20030103985A1 (en) 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
US7470428B2 (en) 2002-01-30 2008-12-30 The Brigham And Women's Hospital, Inc. Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
EP1501351A2 (fr) 2002-04-17 2005-02-02 Richard Metz Substitution homologue de fragments courts d'adn permettant d'obtenir des bovins resistants a l'esb
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7824681B2 (en) 2005-08-16 2010-11-02 The United States Of America As Represented By The Department Of Health And Human Services Human monoclonal antibodies that specifically bind IGF-II
LT2468770T (lt) 2006-07-14 2018-05-25 Ac Immune S.A. Humanizuotas antikūnas prieš beta amiloidą
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
EP2444418A3 (fr) 2006-09-08 2012-08-08 Amgen, Inc Variantes de la famille IL-1
PL2109608T3 (pl) 2007-01-10 2011-08-31 Msd Italia Srl Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP)
EP2126105A4 (fr) 2007-02-20 2010-11-03 Anaptysbio Inc Systèmes d'hypermutation somatique
EP2170959B1 (fr) 2007-06-18 2013-10-02 Merck Sharp & Dohme B.V. Anticorps dirigés contre le récepteur humain de mort programmée pd-1
NZ586675A (en) 2008-01-08 2012-04-27 Merck Sharp & Dohme Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
US8012714B2 (en) 2008-04-14 2011-09-06 Innovative Targeting Solutions, Inc. Sequence diversity generation in immunoglobulins
JP2012501184A (ja) 2008-08-28 2012-01-19 ワイス・エルエルシー 自己免疫疾患におけるｉｌ−２２、ｉｌ−１７、およびｉｌ−１ファミリーのサイトカインの使用
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
CA2802344C (fr) 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Anticorps di-specifiques anti-tim-3 et pd-1 pour immunotherapie dans des etats pathologiques immuns chroniques
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2015527869A (ja) 2011-08-26 2015-09-24 メリマック ファーマシューティカルズ インコーポレーティッド タンデムＦｃ二重特異性抗体
EA031948B1 (ru) 2011-11-16 2019-03-29 Бёрингер Ингельхайм Интернациональ Гмбх Антитело к il-36r или его антигенсвязывающий фрагмент, выделенный полинуклеотид, клетка-хозяин и способ получения этого антитела или его фрагмента, содержащая их фармацевтическая композиция и применение антитела или его фрагмента и композиции
WO2013098419A1 (fr) 2011-12-28 2013-07-04 Immunoqure Ag Méthode pour fournir des auto-anticorps monoclonaux à spécificité désirée
CA2876397C (fr) 2012-06-15 2019-08-06 Pfizer Inc. Anticorps antagonistes ameliores diriges contre gdf-8 et leurs utilisations
AU2014248636B2 (en) 2013-03-12 2017-03-30 Decimmune Therapeutics, Inc. Humanized anti-N2 antibodies
CN105209497B (zh) 2013-03-15 2021-09-07 诺和诺德股份有限公司 能够特异性结合组织因子途径抑制物上的两个表位的抗体
SG11201508528TA (en) 2013-05-02 2015-11-27 Anaptysbio Inc Antibodies directed against programmed death-1 (pd-1)
JOP20200096A1 (ar) * 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CU24481B1 (es) 2014-03-14 2020-03-04 Immutep Sas Moléculas de anticuerpo que se unen a lag-3
GB201419094D0 (en) 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
SI3215532T1 (sl) 2014-11-06 2020-02-28 F. Hoffmann-La Roche Ag Protitelesa proti TIM3 in postopki uporabe
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
PT3317301T (pt) 2015-07-29 2021-07-09 Novartis Ag Terapias de associação compreendendo moléculas de anticorpo contra lag-3
SG11201803520PA (en) 2015-11-03 2018-05-30 Janssen Biotech Inc Antibodies specifically binding pd-1 and their uses
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
KR102510996B1 (ko) 2016-06-29 2023-03-16 테사로, 인코포레이티드 난소암의 치료 방법
AU2017317227B2 (en) 2016-08-26 2024-08-01 Beigene, Ltd. Anti-Tim-3 antibodies and use thereof
SG11201903867YA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
CN110382000A (zh) * 2017-01-09 2019-10-25 泰萨罗公司 用抗tim-3抗体治疗癌症的方法
AR111651A1 (es) * 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación

Also Published As

Publication number Publication date
KR20190098263A (ko) 2019-08-21
TW201831196A (zh) 2018-09-01
MX2019008208A (es) 2019-12-11
IL267803A (en) 2019-09-26
TWI841209B (zh) 2024-05-01
BR112019014169A2 (pt) 2020-02-11
TWI793094B (zh) 2023-02-21
CA3049536A1 (fr) 2018-07-12
US20190322746A1 (en) 2019-10-24
TW202319068A (zh) 2023-05-16
KR102671283B1 (ko) 2024-06-03
JP2020503364A (ja) 2020-01-30
WO2018129553A1 (fr) 2018-07-12
AU2018205401A1 (en) 2019-07-25
JP2022087185A (ja) 2022-06-09
US20240301057A1 (en) 2024-09-12
US11926665B2 (en) 2024-03-12
EP3565594A1 (fr) 2019-11-13
CN110382000A (zh) 2019-10-25
SG10201913083SA (en) 2020-03-30
JP7472190B2 (ja) 2024-04-22
JP7118073B2 (ja) 2022-08-15

Similar Documents

Publication Publication Date Title
MA47206A (fr) Méthodes de traitement du cancer au moyen d'anticorps anti-tim-3
MA51631A (fr) Anticorps anti-pd1 et méthodes de traitement
MA46842A (fr) Méthodes de traitement de l'obésité au moyen d'anticorps anti-angptl8
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA50269A (fr) Compositions d'acides nucléiques-polypeptides et méthodes d'induction de saut d'exon
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
MA49295A (fr) Traitements du cancer de l'utérus
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
CU24498B1 (es) Anticuerpos de factor xi
MA55629A (fr) Compositions d'anticorps pour le traitement de tumeurs
MA51677A (fr) Méthodes de traitement du cancer à l'aide d'anticorps anti-pd-1
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
MA52657A (fr) Anticorps spécifiques d'axl pour le traitement du cancer
MA51844A (fr) Méthodes de traitement du cancer avec des anticorps anti pd-1 et des anticorps anti ctla4
MA53329A (fr) Méthodes de traitement de l'épilepsie
MA47504A (fr) Composés et méthodes de traitement de l'angiocholite biliaire primitive
MA49250A (fr) Nouveaux anticorps anti-cd3
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
CO2017001087A2 (es) Anticuerpos anti proteína similar a angiopoyetina 4
MA46353A (fr) Méthodes de traitement de l'infertilité féminine
MA45997A (fr) Méthodes de traitement de la maladie de crohn avec un anticorps anti-nkg2d
MA45552A (fr) Compositions destinées au traitement de l'amylose
MA53831A (fr) Méthodes permettant de réduire l'agrégation d'anticorps bispécifiques
MA51678A (fr) Méthodes de traitement de l'amyotrophie musculaire